Johnson & Johnson FDA - Search News

US FDA approves new nasal spray for depression treatment

Hosted on MSN · 11h

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.

Popular Science · 20h

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

CNN on MSN · 1d

FDA approves standalone use of J&J’s ketamine-derived depression treatment

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

1d

Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...

1d

J&J Tops Quarterly Profit Estimates on Cancer Drug Sales

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results